Business Context and Reporting Period
This Form 6-K filing by Aegon Ltd., dated April 15, 2026, announces a strategic divestment of its UK operations. Aegon, an international financial services holding company domiciled in Bermuda with its principal place of business in the Netherlands, aims to become a leading US life insurance and retirement group. The filing details the agreement to sell Aegon UK to Standard Life plc.
Key Financial Metrics and Transaction Details
- Total Consideration: GBP 2.0 billion.
- Consideration Structure:
- Cash: GBP 0.75 billion (subject to deduction of remittances between signing and closing).
- Equity: 15.3% shareholding (181.1 million shares) in Standard Life plc.
- Valuation Multiples: Equivalent to 14.2x 2025 operating result after tax and 1.9x 2025 IFRS Shareholder's equity.
- 2025 Aegon UK Baseline Figures: Operating result after tax of GBP 143 million; Shareholders' equity of GBP 1,077 million.
- Pro Forma Financial Impact (2025 Basis):
- Positive impact on Group shareholders' equity: EUR 1.1 billion.
- Negative impact on Group Valuation Equity: EUR 0.1 billion (due to loss of Contractual Service Margin exceeding equity effect).
- Positive impact on Group net result: EUR 0.6 billion.
- Group Solvency ratio reduction: Approximately 5 percentage points (prior to deleveraging).
Material Changes and Strategic Shifts
The transaction marks the completion of the strategic review of Aegon UK, shifting the company's focus toward the US market. Key changes include:
- Asset Management Retention: Aegon's asset management activities in the UK will remain part of its global asset manager and serve as a partner to the new combined business.
- Accounting Treatment: Until completion, Aegon UK will no longer contribute to the Group Operating result or Operating Capital Generation; its IFRS result will be reported under "Other income/(charges)".
- Corporate Governance: Aegon is entitled to appoint one non-Executive Director to the Board of Standard Life.
- Use of Proceeds: Cash proceeds (net of remittances) will be used for deleveraging and share buybacks.
Guidance, Outlook, and Risks
Aegon will update its 2026-2027 financial ambitions to reflect the divestment, maintaining target growth rates from an adjusted base level.
- Operating Result Run-Rate: Expected to grow ~5% annually (2025-2027) from a pro forma 2025 run-rate of EUR 1.3–1.5 billion.
- OCG (Operating Capital Generation): Expected to grow 0–5% annually from a pro forma 2025 run-rate of EUR 0.7–0.75 billion.
- Free Cash Flow: Expected to increase ~5% annually. The run-rate will be adjusted to remove the UK contribution (EUR 120 million in 2025 terms) and incorporate cash flow from the new equity stake.
- Dividend Growth: Expected to exceed 5% per annum.
- Closing Timeline: Expected around the end of 2026, subject to regulatory approvals.
- Lock-Up Period: Aegon will be subject to a lock-up on Standard Life shares for 18 months post-closing or until the completion of Aegon's redomiciliation to the US, whichever is earlier.
Risks and Contingencies: The filing highlights risks related to regulatory approvals, market volatility, interest rate changes, currency fluctuations (EUR/USD, EUR/GBP), and the uncertainty surrounding the planned relocation of Aegon's legal domicile to the United States.
Investor Verification Checklist
- Confirm the final closing date and receipt of regulatory approvals, as the transaction is expected to close end of 2026.
- Verify the exact cash proceeds after the deduction of remittances taken from Aegon UK between signing and closing.
- Monitor the updated 2026-2027 financial guidance once formally released to confirm the adjusted base levels.
- Track the execution of deleveraging and share buyback programs using the transaction proceeds.
- Assess the impact of the 5% point reduction in the Group Solvency ratio on capital adequacy and dividend capacity.
- Review the progress of Aegon's redomiciliation to the US, which affects the lock-up period on the Standard Life stake.